Author:
Schofield Ryan C.,Scordo Michael,Shah Gunjan,Carlow Dean C.
Reference16 articles.
1. Van der Wall E, Beijnen JH, Rodenhuis S (1995) High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 21(2):105–132
2. Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S (2001) Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 28(2):173–180
3. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, Wall EVD, Slaper-Cortenbach IC (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14:1473–1483
4. Rodenhuis S, Baars JW, Schoraagel JH, Vlasveld LT, Mandjes I, Pinedo HM, Richel DJ (1992) Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantion incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 3(10):855–860
5. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, Singher LJ, Ettinger LJ, Gillespie A, Sam J, Poplack DG (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49(3):736–741